Leqembi (lecanemab-irmb) has potential interactions with other medications. These interactions could cause harmful effects. An interaction can occur because one substance causes another substance ...

Helix has released a new suite of pharmacogenomics (PGx) tests, widening its portfolio in neurology and oncology.

Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.

Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...

The FDA approved a test that can help clinicians diagnose Alzheimer's disease early on using a simple blood draw. The test ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, Tax Shelters, Insurance bonds. Healthy returns: Japan’s assault on old-age di ...

CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference ...

The Lumipulse blood test became the first “in vitro diagnostic device” to be endorsed by the U.S. Food and Drug ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusions needed to one per month.